Alfuzosin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 57237-114

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 57237-114). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Alfuzosin Fig1)

Figure 1 (Alfuzosin Fig1)
This is a study report showing the mean (SEM) Alfuzosin Plasma Concentration-Time Profiles after the administration of Alfuzosin Hydrochloride Extended-Release Tablets 10 mg to 8 healthy middle-aged male volunteers in fed and fasted states. The graph depicted (Figure 1) shows the plasma concentration of alfuzosin (in ng/mL) at different times up to 24 hours.*
FDA Label Image

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)
The text appears to be a figure caption from a clinical trial report. It shows the mean change in IPSS (International Prostate Symptom Score) Total Symptom Score for Trial 1, after treatment with placebo and alfuzosin hydrochloride. The significance level of the difference between the treatments is also shown as p <0.001.*
FDA Label Image

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)
FDA Label Image

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)
FDA Label Image

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)
FDA Label Image

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)
FDA Label Image

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)
The text describes Figure 7, which shows the mean change from baseline in peak urine flow rate (in uL/s) over days of treatment. The data is from Trial 3, and the text includes a code or measurement of some sort (P& ~ rwacmo grasn _-m- survzosm svamocionme oe1s). The code is likely irrelevant to interpreting the figure and may be a result of errors.*
FDA Label Image

Package Label-principal Display Panel (10 mg (30 Tablets Bottle))

Package Label-principal Display Panel (10 mg (30 Tablets Bottle))
This is a medication called Alfuzosin hydrochloride, available in the form of film-coated extended-release tablets of 10mg. The tablets are distributed by Rising Health, LLC and dispensed in a tight, light-resistant container as described in the USP. The usual dosage and administration details are mentioned in the package insert. The tablets should be stored at 20-25°C and protected from light and moisture. The medication is manufactured in India and the code for this particular drug is TS/DRUGS/19/1993 - S. The label also includes information on the packaging, permitted excursions of temperature, and precautions for use, such as keeping the drug out of the reach of children.*
FDA Label Image

Chemical Structure (Alfuzosin Str)

Chemical Structure (Alfuzosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.